NCT03376529View on ClinicalTrials.gov

Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 10, 2017

Primary Completion Date

December 19, 2017

Study Completion Date

December 20, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

SPR741

400 mg IV over 1 hour

DRUG

Ceftazidime

1.0 gram IV over 1 hour

DRUG

Piperacillin/tazobactam

4.5 grams IV over 1 hour

DRUG

Aztreonam

1.0 gram IV over 1 hour

Trial Locations (1)

CF48 4DR

Simbec Research, Ltd., Merthyr Tydfil

Sponsors

Lead Sponsor

Spero Therapeutics
All Listed Sponsors
collaborator

Simbec Research

INDUSTRY

collaborator

QPS Holdings LLC

INDUSTRY

lead

Spero Therapeutics

INDUSTRY